Renal Cancer Clinical Trial
Official title:
Evaluation of the Off-Clamp Robot-Assisted Partial Nephrectomy Technique in the Management of Renal Tumors
Verified date | July 2022 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to compare the effects on kidney function after performing the removal of a kidney tumor with or without clamping the blood vessels during surgery.
Status | Completed |
Enrollment | 80 |
Est. completion date | December 31, 2020 |
Est. primary completion date | May 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients 18 and older. - Patients willing and able to sign consent. - Patients with an organ confined renal mass planning to undergo a robotic assisted partial nephrectomy (RAPN). - Patient with Karnofsky Performance Status (KPS) equal to or greater than 40. Exclusion Criteria: - Patients under 18. - Patients with Karnofsky Performance Status (KPS) less than 40. - Patients with non-organ confined renal masses (invading renal vein, inferior vena cava, peri-renal tissue, ipsilateral adrenal gland, or metastasis). - Patients with bilateral synchronous renal masses. - Patients who can not discontinue Plavix, Coumadin or other anti-platelet or anti-coagulant medications. - Patients with renal lesions determined to be too complex to perform a RAPN without clamp by the surgeon. (The renal mass may be deemed too difficult based on pre-operatively radiological findings. The surgeon's decision to exclude a mass from a robotic assisted partial nephrectomy would be based on a higher risk of positive margin or complication if a RAPN was performed.) |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Midwest Stone Institute. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change From Baseline in eGFR | Renal function following nephrectomy with and without clamping will be assessed using: percent change in eGFR from baseline to 3 months post nephrectomy. | baseline and 3 months post nephrectomy | |
Primary | Percent Change From Baseline in Split Renal Function | Renal function following nephrectomy with and without clamping will be assessed using: percent change in split renal function from baseline to 3 months post nephrectomy. | baseline to 3 months post nephrectomy | |
Secondary | Percent of Observations With Positive Surgical Margins. | Oncologic outcomes will be assessed at the time of nephrectomy based on percent of observations with positive surgical margins. | at the time of nephrectomy | |
Secondary | Estimated Blood Loss | Perioperative outcomes will be assessed based on estimated blood loss at the time of nephrectomy. | At the time of nephrectomy | |
Secondary | Percent of Observations With Metastasis | Oncologic outcomes will be assessed based on percent of observations with metastasis on follow-up imaging at 3 years post nephrectomy. | 3 years | |
Secondary | Operative Time Measured in Minutes. | Perioperative outcomes will be assessed based on operative time measured in minutes at the time of nephrectomy. | At the time of nephrectomy | |
Secondary | Warm Ischemia Time Measured in Minutes. | Perioperative outcomes will be assessed based on warm ischemia time measured in minutes at the time of nephrectomy. | At the time of nephrectomy. | |
Secondary | Percent of Observations With Intra-operative Complications. | Perioperative outcomes will be assessed based on percent of observations with intra-operative complications at the time of nephrectomy. | At the time of nephrectomy | |
Secondary | Number of Hospital Days Post Nephrectomy. | Perioperative outcomes will be assessed based number of hospital days post nephrectomy. | Day of nephrectomy to day of hospital discharge. | |
Secondary | Percent of Observations With Postoperative Complications. | Perioperative outcomes will be assessed based on percent of observations with postoperative complications. | Within 3 months post nephrectomy. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |